Search

Displaying results 7781 - 7790 of 8171 in total
  1. Drug

    Copper gluconate

    go.drugbank.com/drugs/DB11246
    ApprovedInvestigational

    Copper gluconate is a copper salt of D-gluconic acid that displays a light blue to bluish-green color.

  2. Drug

    Pine needle oil (pinus mugo)

    go.drugbank.com/drugs/DB11276
    Approved

    Major components of pine needle oil (pinus mugo) include α-Pinene, β-pinene, δ-3-carene, limonene, β-phellandrene, (E)-caryophyllene, and germacrene D.

  3. Drug

    Carbomycin

    go.drugbank.com/drugs/DB11383
    ExperimentalVet approved

    Carbomycin, also called magnamycin, is crystalline macrolide antibiotic. This antibacterial is obtained from Streptomyces halstedii and it presents a large inhibitory effect against Gram-positive bacteria and some Mycoplasma strains. The...

    Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors
  4. Drug

    Eprinomectin

    go.drugbank.com/drugs/DB11405
    ExperimentalVet approved

    Categories: P-glycoprotein substrates, Cytochrome P-450 CYP3A Inhibitors
  5. Drug

    Cloprostenol

    go.drugbank.com/drugs/DB11507
    ExperimentalVet approved

    Products: GESTAVET PROST (d-cloprostenol 75 mcg/ml solution for injection)
  6. Drug

    Salinomycin

    go.drugbank.com/drugs/DB11544
    ExperimentalVet approved

    Categories: P-glycoprotein inhibitors
  7. Drug

    Insulin tregopil

    go.drugbank.com/drugs/DB11568
    Investigational

    Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 Enzyme Inducers
  8. Drug

    Rupatadine

    go.drugbank.com/drugs/DB11614
    ApprovedInvestigational

    Rupatadine is a dual histamine H1 receptor and platelet activating factor receptor antagonist that is used for symptomatic relief in seasonal and perennial rhinitis as well as chronic spontaneous urticaria. It was approved for marketing ...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 Substrates
  9. Drug

    Tucatinib

    go.drugbank.com/drugs/DB11652
    ApprovedInvestigational

    Tucatinib is a kinase inhibitor drug used with trastuzumab and capecitabine in the treatment of unresectable or metastatic HER-2 positive breast cancer. It was developed by Seattle Genetics and approved by the FDA on April 17, 2020. Tuca...

    Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitors
  10. Drug

    Bryostatin 1

    go.drugbank.com/drugs/DB11752
    Investigational

    Bryostatin 1 has been investigated for the treatment of HIV Infection and Alzheimer's Disease.

    Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors